Statement: The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort.
Primary_evidence: Outcome Measurement:    Overall Response Rate (ORR)   ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.   Time frame: Disease was evaluated radiologically at baseline and every 9 weeks on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months (Cohort 2) Results 1:    Arm/Group Title: Cohort 1: HR+/HER2-   Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle   Participants remained on single agent eribulin until disease progression or withdrawal for other reasons.   Overall Number of Participants Analyzed: 45   Measure Type: Number   Unit of Measure: percentage of participants  35.6        (24 to 49) Results 2:    Arm/Group Title: Cohort 2: TNBC   Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle   Participants remained on single agent eribulin until disease progression or withdrawal for other reasons.   Overall Number of Participants Analyzed: 38   Measure Type: Number   Unit of Measure: percentage of participants  13.2        (5 to 26)